These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Application of monoclonal antibody OC 125 in gynecological oncology].
    Author: Wu AR, Wang EY, Wang XX, Jia XH, Li L.
    Journal: Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653.
    Abstract:
    This study was undertaken to determine whether the measurement of CA125 could effect an early diagnosis and a method for monitoring the course of gynecologic tumors. CA 125 in serum of 195 patients, including 15 apparently healthy women; 39 benign gynecologic tumors; 2 borderline ovarian tumors; 139 malignancies were measured by CENTOCOR cancer antigen 125 kits. Diagnosis of all patients was confirmed by pathology. None of the healthy women; 10% of benign tumors; 78% of epithelial ovarian cancers; 31% of endometrial adenocarcinomas and one out of five adenocarcinoma of uterine cervix had CA 125 level over 65 U/ml. In addition, 23 cases of ovarian cancer were monitored serially up to 9 months. In more than 80% of these patients, CA 125 levels were correlated with the regression or progression of the disease. The significance of this assay for early diagnosis and monitoring the course of ovarian cancer is discussed. It is considered that CA 125 is a promising and useful antigenic marker for monitoring the course of ovarian cancers.
    [Abstract] [Full Text] [Related] [New Search]